ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS

Karan Dixit; Priya Kumthekar; Timothy Kruser; Sean Sachdev; John A Kalapurakal; Vinai Gondi; Sean Grimm; Martin Nicholas; Rimas V Lukas; Steven J Chmura; Minesh P Mehta; Jeffrey Raizer

doi:10.1093/neuonc/nox168.073

ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS

Karan Dixit
, Priya Kumthekar
, Timothy Kruser
, Sean Sachdev
, John A Kalapurakal
, Vinai Gondi
, Sean Grimm
, Martin Nicholas
, Rimas V Lukas
, Steven J Chmura
, Minesh P Mehta
, Jeffrey Raizer

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	19
DOIs	https://doi.org/10.1093/neuonc/nox168.073
State	Published - Nov 6 2017

Access to Document

10.1093/neuonc/nox168.073License: Unspecified

Cite this

Dixit, K., Kumthekar, P., Kruser, T., Sachdev, S., Kalapurakal, J. A., Gondi, V., Grimm, S., Nicholas, M., Lukas, R. V., Chmura, S. J., Mehta, M. P., & Raizer, J. (2017). ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS. Neuro-oncology, 19. https://doi.org/10.1093/neuonc/nox168.073

Dixit, K, Kumthekar, P, Kruser, T, Sachdev, S, Kalapurakal, JA, Gondi, V, Grimm, S, Nicholas, M, Lukas, RV, Chmura, SJ, Mehta, MP & Raizer, J 2017, 'ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS', Neuro-oncology, vol. 19. https://doi.org/10.1093/neuonc/nox168.073

@article{00adb8de1cb54441a2595381e7d1152a,

title = "ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS",

author = "Karan Dixit and Priya Kumthekar and Timothy Kruser and Sean Sachdev and Kalapurakal, \{John A\} and Vinai Gondi and Sean Grimm and Martin Nicholas and Lukas, \{Rimas V\} and Chmura, \{Steven J\} and Mehta, \{Minesh P\} and Jeffrey Raizer",

note = "BACKGROUNDPatients with recurrent high grade glioma (rHGG) have a poor prognosis with limited treatment options, especially those refractory to bevacizumab. A phase II multi-center trial was performed to determine the overall survival (OS) of hypofractioned radiation with concurrent bevacizumab (BEV) and temozolomide (TMZ) followed by maintenance BEV and TMZ in patients with rHGG.METHODSInclusion criteria were recurrent anaplastic glioma (AG) or glioblastoma (GBM) with patients stratified into 4 groups based on histologic grade and prior exposure to bevacizumab (Bev).",

year = "2017",

month = nov,

day = "6",

doi = "10.1093/neuonc/nox168.073",

language = "American English",

volume = "19",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS

AU - Dixit, Karan

AU - Kumthekar, Priya

AU - Kruser, Timothy

AU - Sachdev, Sean

AU - Kalapurakal, John A

AU - Gondi, Vinai

AU - Grimm, Sean

AU - Nicholas, Martin

AU - Lukas, Rimas V

AU - Chmura, Steven J

AU - Mehta, Minesh P

AU - Raizer, Jeffrey

N1 - BACKGROUNDPatients with recurrent high grade glioma (rHGG) have a poor prognosis with limited treatment options, especially those refractory to bevacizumab. A phase II multi-center trial was performed to determine the overall survival (OS) of hypofractioned radiation with concurrent bevacizumab (BEV) and temozolomide (TMZ) followed by maintenance BEV and TMZ in patients with rHGG.METHODSInclusion criteria were recurrent anaplastic glioma (AG) or glioblastoma (GBM) with patients stratified into 4 groups based on histologic grade and prior exposure to bevacizumab (Bev).

PY - 2017/11/6

Y1 - 2017/11/6

UR - http://academic.oup.com/neuro-oncology/article/19/suppl_6/vi19/4590367

U2 - 10.1093/neuonc/nox168.073

DO - 10.1093/neuonc/nox168.073

M3 - Article

VL - 19

JO - Neuro-oncology

JF - Neuro-oncology

ER -

ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS

Access to Document

Other files and links

Cite this